Abstract
A major challenge for using native and modified T cell epitopes to induce or suppress immunity relates to achieving efficient uptake and processing by antigen-presenting cells (APC) in vivo. IgG Fc receptors, which are expressed constitutively by professional APC including monocytes and dendritic cells, have long been known to mediate antigen uptake in a manner leading to efficient T cell activation. We have previously demonstrated enhanced presentation of antigenic and antagonistic peptides by targeting them to the type I Fc receptor for IgG (FcγRI, CD64) on human monocytes. In the present report we review the literature suggesting that CD64-targeted antigens are likely to be effective in vivo, and present data demonstrating enhanced immunogenicity in CD64 transgenic mice of a fusion protein that combines the specificities of HIV gp120 and the humanized anti-CD64 monoclonal antibody H22. Overall, these studies suggest that targeting antigens to CD64 represents an effective approach to enhancing the effectiveness of vaccines in vivo.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Accepted: 14 October 1997
Rights and permissions
About this article
Cite this article
Guyre, P., Graziano, R., Goldstein, J. et al. Increased potency of Fc-receptor-targeted antigens. Cancer Immunol Immunother 45, 146–148 (1997). https://doi.org/10.1007/s002620050418
Issue Date:
DOI: https://doi.org/10.1007/s002620050418